Using patient-derived organoids to personalize ovarian cancer treatments
Official title: Patients Derived Organoids as a Promising Tool to Tailor Ovarian Cancer Therapies (PANDORA)
Run by Centro di Riferimento Oncologico - Aviano · NCT06229522 · Data updated 2026-11-12
This study is testing if using tiny lab-grown versions of ovarian cancer tumors from patients can help doctors find the best treatments for them.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | Women only |
| Enrollment | 150 (estimated) |
| Sponsor | Centro di Riferimento Oncologico - Aviano Academic / other |
| Locations | 1 site (Aviano, Pordenone) |
| Status | Recruiting |
| Started | November 16, 2023 |
| Main results expected | December 31, 2037 |
| Study ends | December 31, 2037 |
| Registry record updated | January 29, 2024 |
| Trial ID | NCT06229522 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are female patients aged 18 and older who have been diagnosed with ovarian cancer and can provide a tumor sample for research.
✕Probably not a fit
Patients who are pregnant, breastfeeding, or have a history of other malignancies in the last five years may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to enhance ovarian cancer therapies by utilizing patient-derived organoids to test the sensitivity of tumors to various treatments. By correlating the treatment responses observed in these organoids with clinical outcomes in real-world patients, the research seeks to identify predictive biomarkers that could guide therapy choices. The study focuses on patients with ovarian cancer who provide tumor samples for analysis, allowing for a personalized approach to treatment. The ultimate goal is to improve survival rates and treatment efficacy for ovarian cancer patients.
Why it matters
Potential benefit: If successful, this approach could lead to more effective and personalized treatment options for ovarian cancer patients.
How similar studies have gone: While the use of patient-derived organoids is a promising approach, it is still relatively novel and has not been extensively tested in similar studies for ovarian cancer.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Signed informed consent form; 2. Female sex; 3. Age ≥18 years; 4. Diagnosis of ovarian cancer; 5. Availability of tumor sample or ascites that is planned to be stored in the Institutional Biobank for research purpose Exclusion Criteria: 1. Patients for which the tumor/ascites biobanking process could compromise the diagnostic assessments; 2. Pregnancy or breast-feeding 3. History of concomitant or previous malignancy in the last 5 years
Where it's running
-
Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS
Aviano, Pordenone, Italy Recruiting
Study contacts
- Principal investigator: Vincenzo Canzonieri, MD — Centro di Riferimento Oncologico di Aviano (CRO) - IRCCS
- Study coordinator: Vincenzo Canzonieri, MD
- Email: vcanzonieri@cro.it
- Phone: 0434659618
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
CG-7321: a first-in-human test in advanced solid tumors
We’re testing CG-7321 alone and with fulvestrant to see if it’s safe and tolerable in adults with advanced solid tumors.
-
CR-002 study in adults with advanced solid tumors
This trial tests CR-002 as a single therapy to see if it is safe and tolerable in adults with locally advanced or metastatic solid tumors
-
VT-101 in Advanced Ovarian Cancer: early safety study in adults
This early-phase trial tests VT-101 in adult women with advanced, recurrent, or relapsed epithelial ovarian cancer to see if it is safe, how the body handles it, and whether there are any initial signs of activity.
-
Methylation markers in self-samples to help detect gynecological cancers
This study tests whether self-collected urine and vaginal samples can reveal DNA methylation or other genetic markers that indicate endometrial, ovarian, vulvar, or vaginal cancers in women who are at risk or have postmenopausal bleeding.
-
Radiotherapy for gynecologic cancer with up to 10 metastatic sites
This registry follows adults with gynecologic cancer who have 1 to 10 active metastatic lesions and are treated with radiotherapy as part of routine care to see how such treatments work in real-world settings.
-
EHR-based approach to boost HBOC genetic testing in at-risk women
A new EHR tool-based program tests whether computer prompts and real patient resources can help more women with family histories of breast or ovarian cancer get HBOC genetic testing.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.